Delivery Order SPE2DR25D2006-SPE2DR26F56FJ
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for 36,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count bottles, valued at $31,396.02. This firm fixed price delivery order, which represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX, valued at $999,999,999.00 through December 2026), was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Creon DR 36,000 unit capsules in units of 100, with a contract ceiling value of $2,335.13 and an ultimate completion date of July 24, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Creon DR 24,000 unit capsules (100 count) with a ceiling value of $2,262.52 and an ultimate completion date of August 11, 2025. This is a firm fixed price, non-set-aside contract with performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Creon DR 36,000 Unit Capsule UU 100s, a pancreatic enzyme replacement medication. This non-competitive delivery order, valued at $3,116.73 with a firm fixed price structure, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The order is scheduled for completion by July 22, 2025, and will be fulfilled...
- The Defense Logistics Agency awarded a $21,057.57 delivery order to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count bottles. This firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for completion by September 11, 2025. AmerisourceBergen will perform this delivery order from its corporate headquarters in Conshohocken, Pennsylvania, where the company operates as a major...
- The Defense Logistics Agency awarded a delivery order valued at $9,025.18 to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count bottles. This firm fixed price delivery order, issued on August 11, 2025, with an ultimate completion date of August 12, 2025, represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Creon DR 36,000 unit capsules in 100-count bottles, with a ceiling value of $2,424.24 and an ultimate completion date of June 3, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was competitively procured. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on October 20, 2025, by the Defense Logistics Agency for 36,000 unit capsules of Creon DR 100s at a ceiling value of $12,598.12. This firm fixed-price delivery order, with an ultimate completion date of October 21, 2025, was competitively awarded with no set-aside designation and represents a child contract under AmerisourceBergen's larger federal contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for 24,000 units of Creon DR 100s capsules, a pancreatic enzyme supplement medication. This competitively awarded, non-set-aside contract carries a ceiling value of $3,042.77 and is classified as a firm fixed price delivery order with an ultimate completion date of August 27, 2025. The contract will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $10,494.25 to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon DR 100s on November 17, 2025, with completion expected by November 18, 2025. This firm fixed-price, competitively awarded delivery order represents a continuation of the vendor's pharmaceutical supply support to federal military and healthcare systems. The contract was executed under a non-set-aside procurement process, underscoring AmerisourceBergen's...
- SPE2DR25D2006Indefinite Delivery Contract
- SPE2DR25D2006-SPE2DR26F56FJDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 20, 2025, for the supply of 36,000 unit capsules of Creon (a pancreatic enzyme replacement therapy) in 100-count bottles, with a contract ceiling value of $37,725.58. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through open competition. The contract is classified as a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle valued through December 2026 that enables the company to supply pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement across the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's extensive federal contract portfolio demonstrates its capability to fulfill diverse pharmaceutical and medical supply requirements, ranging from specialty medications and generic drugs to vaccines and medical devices. This delivery order represents routine pharmaceutical fulfillment under the company's established prime vendor agreement with DLA, with performance scheduled for completion by November 21, 2025.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $37.7k | 11/20/25 |